1 patent currently held
22 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2028. from the record
Of the 22 now held by other companies, 10 name Vertex Pharmaceuticals Incorporated as their current owner, and 12 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jul 2028
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Mar 2031 · High confidence
Cited by 66 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Uswm Development Co., LLC
Also notable
Ends Oct 2030 · High confidence
The most cited patent in this portfolio, cited by 77 later US patents, top 10% of utility patents granted in 2012 in our data. Protection runs to 2030.
now held by Vertex Pharmaceuticals Incorporated
Also notable
Ends Jan 2029 · High confidence
Cited by 31 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Trames Bio, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 2 terms have ended since Aug 17, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,765,726 | Use of Pyridone Derivatives in the Prevention or Treatment of Tissue or Organ Toxicity Induced by Cytotoxic Agents and Radiation In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 22 patents in force now held by others · 31 patents ended · 1 application pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
7 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
15 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.